Transcription Factor Stat3 in Metastatic Progression of Prostate Cancer
Annual rept. 31 Oct 2005-30 May 2007
THOMAS JEFFERSON UNIV PHILADELPHIA PA
Pagination or Media Count:
The majority of prostate cancer fatalities are caused by development of androgen-independent growth of prostate cancer and metastatic spread of the primary tumor. There are currently no effective treatments for androgen-independent and metastatic prostate cancer. Moreover, the molecular mechanisms underlying progression of prostate cancer from primary tumor to metastasis remains a complex and poorly understood process. Identification of new therapeutic target proteins and identification of the molecular changes that lead to metastatic progression will be critical for development of better therapeutic intervention of prostate cancer and for development of an effective strategy to prevent progression of human prostate cancer. The other major problem in clinical management of prostate cancer is a lack of reliable prognostic markers for identification of prostate cancers that are likely to progress to aggressive metastatic disease. Since the detection and diagnosis of early stage prostate cancers have significantly improved over the last five years and since the clinical course of prostate cancer is highly variable, it is of utmost importance to develop effective prognostic markers to identify prostate cancers that are likely to progress aggressively to hormone-refractory and metastatic disease.
- Anatomy and Physiology
- Medicine and Medical Research